Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 690 results for innovative

  1. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

  2. Preventing excess weight gain (NG7)

    This guideline covers behaviours such as diet and physical activity to help children (after weaning), young people and adults maintain a healthy weight or help prevent excess weight gain. The aim is to prevent a range of diseases and conditions including cardiovascular disease and type 2 diabetes and improve mental wellbeing.

  3. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

  4. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

  5. Eltrombopag for treating chronic immune thrombocytopenia (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

  6. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

  7. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

  8. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

  9. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

  10. NICE health technology evaluation topic selection: the manual (PMG37)

    This is not the current manual. From 29 May 2024, health technologies are selected using the new NICE-wide topic prioritisation process (PMG46)

  11. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

  12. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  13. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

    Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.

  14. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

  15. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.